{"id":"https://openalex.org/W3082458287","doi":"https://doi.org/10.1158/1538-7445.am2020-3376","title":"Abstract 3376: HER2-XPAT and EGFR-XPAT: Pro-drug T-cell engagers (TCEs) engineered to address on-target, off-tumor toxicity with potent efficacy in vitro and in vivo and large safety margins in NHP","display_name":"Abstract 3376: HER2-XPAT and EGFR-XPAT: Pro-drug T-cell engagers (TCEs) engineered to address on-target, off-tumor toxicity with potent efficacy in vitro and in vivo and large safety margins in NHP","publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3082458287","doi":"https://doi.org/10.1158/1538-7445.am2020-3376","mag":"3082458287"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-3376","doi":"https://doi.org/10.1158/1538-7445.am2020-3376","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-3376","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033675619","display_name":"Fiore Cattaruzza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fiore Cattaruzza","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111147020","display_name":"Ayesha Nazeer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayesha Nazeer","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051527877","display_name":"Zachary Lange","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zachary Lange","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071941321","display_name":"Mikhail Hammond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikhail Hammond","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059098189","display_name":"Caitlin Koski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caitlin Koski","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026185277","display_name":"Angela Henkensiefken","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela Henkensiefken","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049851359","display_name":"Mika Kakefuda Derynck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mika K. Derynck","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030418854","display_name":"Bryan A. Irving","orcid":"https://orcid.org/0000-0002-5093-013X","observed_orcids":["https://orcid.org/0000-0002-5093-013X"]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Irving","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018783910","display_name":"Volker Schellenberger","orcid":"https://orcid.org/0000-0002-3491-8229","observed_orcids":["https://orcid.org/0000-0002-3491-8229"]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Volker Schellenberger","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210131535"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"3376","last_page":"3376"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.5922999978065491,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.5922999978065491,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.17000000178813934,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.09390000253915787,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/t-cell-engagers","display_name":"T-cell engagers","score":0.8080000281333923},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.6759999990463257},{"id":"https://openalex.org/keywords/on-target-off-tumor-toxicity","display_name":"on-target off-tumor toxicity","score":0.9670000076293945},{"id":"https://openalex.org/keywords/therapeutic-index","display_name":"therapeutic index","score":0.7160000205039978},{"id":"https://openalex.org/keywords/tumor-antigen-targeting","display_name":"tumor antigen targeting","score":0.4749999940395355},{"id":"https://openalex.org/keywords/xenograft-tumor-model","display_name":"xenograft tumor model","score":0.546999990940094},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.4970000088214874},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.4410000145435333}],"concepts":[{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5996783971786499},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.5705869793891907},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5107786655426025},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.4699293076992035},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4466097354888916},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4146949052810669},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.400905579328537},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.23752325773239136},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1474609375},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.12497061491012573},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-3376","doi":"https://doi.org/10.1158/1538-7445.am2020-3376","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-3376","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3088857581","https://openalex.org/W3094976805","https://openalex.org/W3112347154","https://openalex.org/W3133482751","https://openalex.org/W3180038610","https://openalex.org/W4298121561","https://openalex.org/W4362459740","https://openalex.org/W4200193838","https://openalex.org/W3088648667","https://openalex.org/W4282982885"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"TCEs":[2,405],"have":[3,16,32,42],"proven":[4],"to":[5,23,47,114,144,318,410,453],"be":[6,422],"effective":[7],"in":[8,12,19,77,140,188,191,200,214,244,255,304,321,392,461,464,470],"creating":[9],"durable":[10],"remissions":[11],"hematologic":[13],"malignancies":[14],"but":[15,40],"been":[17,44,314],"challenging":[18],"solid":[20],"tumors":[21,78],"due":[22,46],"on-target,":[24,455],"off-tumor":[25,456],"toxicity.":[26,414],"To":[27,52],"circumvent":[28],"the":[29,63,73,85,92,115,129,141,156,176,226,268,274,277,327,353,395,403,476,480],"toxicity,":[30],"many":[31],"tried":[33],"step-up,":[34],"fractionated":[35],"dosing":[36],"or":[37,65,302],"complex":[38],"formats,":[39],"these":[41,132],"largely":[43],"unsuccessful":[45],"toxicity":[48,196,457],"and/or":[49],"enhanced":[50],"immunogenicity.":[51],"address":[53,454],"this":[54],"challenge,":[55],"Amunix":[56],"has":[57,313],"developed":[58],"a":[59,102,146,151,169,297,337,387,407],"conditionally":[60],"active":[61],"TCE,":[62],"XPAT":[64,93,228,308,404],"XTENylated":[66],"Protease-Activated":[67],"T":[68,216,372],"Cell":[69],"Engager,":[70],"that":[71,117],"exploits":[72],"protease":[74],"activity":[75,173,350,385],"present":[76],"vs.":[79],"healthy":[80],"tissue,":[81],"enabling":[82],"expansion":[83],"of":[84,91,95,131,174,208,265,293,307,336,348,361,382,390,400,475,479],"therapeutic":[86],"index":[87],"(TI).":[88],"The":[89,172],"core":[90,116],"consists":[94],"2":[96,299],"tandem":[97],"scFVs":[98],"targeting":[99],"CD3":[100],"and":[101,107,122,160,179,190,210,253,258,270,323,341,368,386,418,446,463,466,490],"tumor":[103,142,221,241],"antigen.":[104],"Two":[105],"unstructured":[106],"modular":[108],"polypeptide":[109,134],"masks":[110,135,378],"(XTEN)":[111],"are":[112,136,370],"attached":[113],"sterically":[118],"reduce":[119],"target":[120,233],"engagement":[121],"extend":[123],"T1/2.":[124],"Protease":[125],"cleavage":[126],"sites":[127],"at":[128,282],"base":[130],"XTEN":[133,377,397],"then":[137],"proteolytically":[138],"released":[139],"microenvironment":[143],"unleash":[145],"highly":[147],"potent":[148,213,383,459],"TCE":[149],"with":[150,248,326,375,379,458],"short":[152],"T1/2,":[153],"further":[154],"improving":[155],"TI.":[157],"Methods:":[158],"HER2-XPAT":[159,211,249,312,369,445],"EGFR-XPATs":[161],"were":[162,184,198,344],"each":[163],"purified":[164],"from":[165,168,334],"E.coli":[166],"expressed":[167],"single":[170,288],"plasmid.":[171],"both":[175,256],"prodrugs":[177],"(XPATs)":[178],"their":[180],"protease-activated":[181,205],"counterparts":[182],"(PATs)":[183,206],"characterized":[185],"for":[186,483],"cytotoxicity":[187,219],"vitro":[189,215,462],"huPBMC-transduced":[192],"tumor-bearing":[193],"mice.":[194],"Pilot":[195],"studies":[197],"conducted":[199],"NHPs":[201],"(cyno).":[202],"Results:":[203],"Both":[204],"forms":[207],"EGFR-XPAT":[209,237,266,367],"demonstrated":[212,238],"cell":[217,234,373],"directed":[218],"against":[220,232],"cells":[222],"(EC50s":[223],"1-2pM),":[224],"while":[225,276],"masked":[227],"provided":[229],"3,000-14,000-fold":[230],"protection":[231,301,391],"killing.":[235],"Intact":[236],"dose-dependent":[239],"complete":[240],"responses":[242],"(CRs)":[243],"HT-29":[245],"CRC":[246],"xenografts,":[247],"demonstrating":[250],"similar":[251],"efficacy":[252,419,460],"CRs":[254],"BT-474":[257],"SK-OV-3":[259],"tumors.":[260],"In":[261],"cynos,":[262],"1":[263,290],"mg/kg":[264,272,320,356],"was":[267,280,324,364],"MTD":[269,328],"1.5":[271],"exceeded":[273],"MTD,":[275],"activated":[278],"PAT":[279],"lethal":[281],"0.132mg/kg/day":[283],"by":[284],"continuous":[285],"infusion":[286],"(with":[287],"dose":[289,315],"hour":[291],"bolus":[292],"0.066ug/kg).":[294],"This":[295],"indicated":[296],"near":[298],"log":[300],"more":[303],"predicted":[305],"Cmax":[306],"vs":[309],"PAT.":[310],"A":[311],"escalated":[316],"up":[317],"21":[319,355],"cynos":[322],"well-tolerated,":[325],"still":[329],"unreached.":[330],"At":[331],"doses":[332],"starting":[333],"2.5mg/kg":[335],"HER2-XPAT,":[338],"lymphocyte":[339],"margination":[340],"laboratory":[342],"abnormalities":[343],"observed,":[345],"indicating":[346],"evidence":[347,381],"biologic":[349],"well":[351],"below":[352],"tolerated":[354],"dose.":[357],"An":[358],"estimated":[359],"T1/2":[360],"~4":[362],"days":[363],"observed.":[365],"Conclusions:":[366],"novel":[371],"engagers":[374,450],"protease-cleavable":[376],"preclinical":[380],"anti-tumor":[384],"wide":[388],"margin":[389],"cynos.":[393],"With":[394],"prior":[396],"clinical":[398],"data":[399,420],"low":[401],"immunogenicity,":[402],"provide":[406],"promising":[408],"solution":[409],"overcome":[411],"On-target,":[412],"Off-tumor":[413],"Additional":[415],"PD,":[416],"safety":[417,468],"will":[421],"presented.":[423],"Citation":[424],"Format:":[425],"Fiore":[426],"Cattaruzza,":[427],"Ayesha":[428],"Nazeer,":[429],"Zachary":[430],"Lange,":[431],"Mikhail":[432],"Hammond,":[433],"Caitlin":[434],"Koski,":[435],"Angela":[436],"Henkensiefken,":[437],"Mika":[438],"K.":[439],"Derynck,":[440],"Bryan":[441],"Irving,":[442],"Volker":[443],"Schellenberger.":[444],"EGFR-XPAT:":[447],"Pro-drug":[448],"T-cell":[449],"(TCEs)":[451],"engineered":[452],"vivo":[465],"large":[467],"margins":[469],"NHP":[471],"[abstract].":[472],"In:":[473],"Proceedings":[474],"Annual":[477],"Meeting":[478],"American":[481],"Association":[482],"Cancer":[484,496],"Research":[485],"2020;":[486],"2020":[487],"Apr":[488],"27-28":[489],"Jun":[491],"22-24.":[492],"Philadelphia":[493],"(PA):":[494],"AACR;":[495],"Res":[497],"2020;80(16":[498],"Suppl):Abstract":[499],"nr":[500],"3376.":[501]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2020-09-08T00:00:00"}